| 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus M Aringer, K Costenbader, D Daikh, R Brinks, M Mosca, ... Arthritis & rheumatology 71 (9), 1400-1412, 2019 | 3500 | 2019 |
| EULAR recommendations for the management of Behçet disease G Hatemi, A Silman, D Bang, B Bodaghi, AM Chamberlain, A Gul, ... Annals of the rheumatic diseases 67 (12), 1656-1662, 2008 | 1049 | 2008 |
| Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study S Dass, SJ Bowman, EM Vital, K Ikeda, CT Pease, J Hamburger, ... Annals of the rheumatic diseases 67 (11), 1541-1544, 2008 | 472 | 2008 |
| EULAR recommendations for the management of systemic lupus erythematosus: 2023 update A Fanouriakis, M Kostopoulou, J Andersen, M Aringer, L Arnaud, SC Bae, ... Annals of the rheumatic diseases 83 (1), 15-29, 2024 | 455 | 2024 |
| Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial RA Furie, EF Morand, IN Bruce, S Manzi, KC Kalunian, EM Vital, TL Ford, ... The Lancet Rheumatology 1 (4), e208-e219, 2019 | 436 | 2019 |
| Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination A Watad, G De Marco, H Mahajna, A Druyan, M Eltity, N Hijazi, A Haddad, ... Vaccines 9 (5), 435, 2021 | 376 | 2021 |
| Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts C Díaz-Lagares, S Croca, S Sangle, EM Vital, F Catapano, ... Autoimmunity reviews 11 (5), 357-364, 2012 | 296 | 2012 |
| Development of psoriasis after B cell depletion with rituximab S Dass, EM Vital, P Emery Arthritis & Rheumatism 56 (8), 2715-2718, 2007 | 290 | 2007 |
| B cell biomarkers of rituximab responses in systemic lupus erythematosus EM Vital, S Dass, MH Buch, K Henshaw, CT Pease, MF Martin, F Ponchel, ... Arthritis & Rheumatism 63 (10), 3038-3047, 2011 | 263 | 2011 |
| Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis S Dass, AC Rawstron, EM Vital, K Henshaw, D McGonagle, P Emery Arthritis & Rheumatism: Official Journal of the American College of …, 2008 | 263 | 2008 |
| Effect of rituximab on the progression of rheumatoid arthritis–related interstitial lung disease: 10 years’ experience at a single centre MY Md Yusof, A Kabia, M Darby, G Lettieri, P Beirne, EM Vital, S Dass, ... Rheumatology 56 (8), 1348-1357, 2017 | 217 | 2017 |
| Type I interferon–mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy A Psarras, P Emery, EM Vital Rheumatology 56 (10), 1662-1675, 2017 | 191 | 2017 |
| Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re‐treatment EM Vital, S Dass, AC Rawstron, MH Buch, V Goeb, K Henshaw, ... Arthritis & Rheumatism 62 (5), 1273-1279, 2010 | 170 | 2010 |
| Effectiveness of belimumab after rituximab in systemic lupus erythematosus: a randomized controlled trial M Shipa, A Embleton-Thirsk, M Parvaz, LR Santos, P Muller, ... Annals of internal medicine 174 (12), 1647-1657, 2021 | 127 | 2021 |
| Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus MYM Yusof, D Shaw, YM El-Sherbiny, E Dunn, AC Rawstron, P Emery, ... Annals of the rheumatic diseases 76 (11), 1829-1836, 2017 | 127 | 2017 |
| A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features YM El-Sherbiny, A Psarras, MY Md Yusof, EMA Hensor, R Tooze, ... Scientific reports 8 (1), 5793, 2018 | 126 | 2018 |
| Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity A Psarras, A Alase, A Antanaviciute, IM Carr, MY Md Yusof, M Wittmann, ... Nature communications 11 (1), 6149, 2020 | 121 | 2020 |
| Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials EM Vital, JT Merrill, EF Morand, RA Furie, IN Bruce, Y Tanaka, S Manzi, ... Annals of the rheumatic diseases 81 (7), 951-961, 2022 | 120 | 2022 |
| Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status MYM Yusof, A Psarras, YM El-Sherbiny, EMA Hensor, K Dutton, ... Annals of the rheumatic diseases 77 (10), 1432-1439, 2018 | 118 | 2018 |
| Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases MY Md Yusof, EM Vital, DM McElvenny, EMA Hensor, S Das, S Dass, ... Arthritis & Rheumatology 71 (11), 1812-1823, 2019 | 116 | 2019 |
Paul EmeryProfessor Rheumatology Leeds, Birmingham MelbourneVerifisert e-postadresse på leeds.ac.uk